Cargando…

COVID-19 infections post-vaccination by HIV status in the United States

IMPORTANCE: Recommendations for additional doses of COVID vaccine are restricted to people with HIV who have advanced disease or unsuppressed HIV viral load. Understanding SARS-CoV-2 infection risk post-vaccination among PWH is essential for informing vaccination guidelines. OBJECTIVE: Estimate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Coburn, Sally B., Humes, Elizabeth, Lang, Raynell, Stewart, Cameron, Hogan, Brenna C, Gebo, Kelly A., Napravnik, Sonia, Edwards, Jessie K., Browne, Lindsay E., Park, Lesley S., Justice, Amy C., Gordon, Kirsha, Horberg, Michael A., Certa, Julia M., Watson, Eric, Jefferson, Celeena R, Silverberg, Michael, Skarbinski, Jacek, Leyden, Wendy A, Williams, Carolyn F., Althoff, Keri N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669858/
https://www.ncbi.nlm.nih.gov/pubmed/34909791
http://dx.doi.org/10.1101/2021.12.02.21267182
_version_ 1784614863434153984
author Coburn, Sally B.
Humes, Elizabeth
Lang, Raynell
Stewart, Cameron
Hogan, Brenna C
Gebo, Kelly A.
Napravnik, Sonia
Edwards, Jessie K.
Browne, Lindsay E.
Park, Lesley S.
Justice, Amy C.
Gordon, Kirsha
Horberg, Michael A.
Certa, Julia M.
Watson, Eric
Jefferson, Celeena R
Silverberg, Michael
Skarbinski, Jacek
Leyden, Wendy A
Williams, Carolyn F.
Althoff, Keri N.
author_facet Coburn, Sally B.
Humes, Elizabeth
Lang, Raynell
Stewart, Cameron
Hogan, Brenna C
Gebo, Kelly A.
Napravnik, Sonia
Edwards, Jessie K.
Browne, Lindsay E.
Park, Lesley S.
Justice, Amy C.
Gordon, Kirsha
Horberg, Michael A.
Certa, Julia M.
Watson, Eric
Jefferson, Celeena R
Silverberg, Michael
Skarbinski, Jacek
Leyden, Wendy A
Williams, Carolyn F.
Althoff, Keri N.
author_sort Coburn, Sally B.
collection PubMed
description IMPORTANCE: Recommendations for additional doses of COVID vaccine are restricted to people with HIV who have advanced disease or unsuppressed HIV viral load. Understanding SARS-CoV-2 infection risk post-vaccination among PWH is essential for informing vaccination guidelines. OBJECTIVE: Estimate the risk of breakthrough infections among fully vaccinated people with (PWH) and without (PWoH) HIV in the US. DESIGN, SETTING, AND PARTICIPANTS: The Corona-Infectious-Virus Epidemiology Team (CIVET)-II cohort collaboration consists of 4 longitudinal cohorts from integrated health systems and academic health centers. Each cohort identified individuals ≥18 years old, in-care, and fully vaccinated for COVID-19 through 30 June 2021. PWH were matched to PWoH on date fully vaccinated, age group, race/ethnicity, and sex at birth. Incidence rates per 1,000 person-years and cumulative incidence of breakthrough infections with 95% confidence intervals ([,]) were estimated by HIV status. Cox proportional hazards models estimated adjusted hazard ratios (aHR) of breakthrough infections by HIV status adjusting for demographic factors, prior COVID-19 illness, vaccine type (BNT162b2, [Pfizer], mRNA-1273 [Moderna], Jansen Ad26.COV2.S [J&J]), calendar time, and cohort. Risk factors for breakthroughs among PWH, were also investigated. EXPOSURE: HIV infection OUTCOME: COVID-19 breakthrough infections, defined as laboratory evidence of SARS-CoV-2 infection or COVID-19 diagnosis after an individual was fully vaccinated. RESULTS: Among 109,599 individuals (31,840 PWH and 77,759 PWoH), the rate of breakthrough infections was higher in PWH versus PWoH: 44 [41, 48] vs. 31 [29, 33] per 1,000 person-years. Cumulative incidence at 210 days after date fully vaccinated was low, albeit higher in PWH versus PWoH overall (2.8% versus 2.1%, log-rank p<0.001, risk difference=0.7% [0.4%, 1.0%]) and within each vaccine type. Breakthrough infection risk was 41% higher in PWH versus PWoH (aHR=1.41 [1.28, 1.56]). Among PWH, younger age (18–24 versus 45–54), history of COVID-19 prior to fully vaccinated date, and J&J vaccination (versus Pfizer) were associated with increased risk of breakthroughs. There was no association of breakthrough with HIV viral load suppression or CD4 count among PWH. CONCLUSIONS AND RELEVANCE: COVID-19 vaccination is effective against infection with SARS-CoV-2 strains circulating through 30 Sept 2021. PWH have an increased risk of breakthrough infections compared to PWoH. Recommendations for additional vaccine doses should be expanded to all PWH.
format Online
Article
Text
id pubmed-8669858
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-86698582021-12-15 COVID-19 infections post-vaccination by HIV status in the United States Coburn, Sally B. Humes, Elizabeth Lang, Raynell Stewart, Cameron Hogan, Brenna C Gebo, Kelly A. Napravnik, Sonia Edwards, Jessie K. Browne, Lindsay E. Park, Lesley S. Justice, Amy C. Gordon, Kirsha Horberg, Michael A. Certa, Julia M. Watson, Eric Jefferson, Celeena R Silverberg, Michael Skarbinski, Jacek Leyden, Wendy A Williams, Carolyn F. Althoff, Keri N. medRxiv Article IMPORTANCE: Recommendations for additional doses of COVID vaccine are restricted to people with HIV who have advanced disease or unsuppressed HIV viral load. Understanding SARS-CoV-2 infection risk post-vaccination among PWH is essential for informing vaccination guidelines. OBJECTIVE: Estimate the risk of breakthrough infections among fully vaccinated people with (PWH) and without (PWoH) HIV in the US. DESIGN, SETTING, AND PARTICIPANTS: The Corona-Infectious-Virus Epidemiology Team (CIVET)-II cohort collaboration consists of 4 longitudinal cohorts from integrated health systems and academic health centers. Each cohort identified individuals ≥18 years old, in-care, and fully vaccinated for COVID-19 through 30 June 2021. PWH were matched to PWoH on date fully vaccinated, age group, race/ethnicity, and sex at birth. Incidence rates per 1,000 person-years and cumulative incidence of breakthrough infections with 95% confidence intervals ([,]) were estimated by HIV status. Cox proportional hazards models estimated adjusted hazard ratios (aHR) of breakthrough infections by HIV status adjusting for demographic factors, prior COVID-19 illness, vaccine type (BNT162b2, [Pfizer], mRNA-1273 [Moderna], Jansen Ad26.COV2.S [J&J]), calendar time, and cohort. Risk factors for breakthroughs among PWH, were also investigated. EXPOSURE: HIV infection OUTCOME: COVID-19 breakthrough infections, defined as laboratory evidence of SARS-CoV-2 infection or COVID-19 diagnosis after an individual was fully vaccinated. RESULTS: Among 109,599 individuals (31,840 PWH and 77,759 PWoH), the rate of breakthrough infections was higher in PWH versus PWoH: 44 [41, 48] vs. 31 [29, 33] per 1,000 person-years. Cumulative incidence at 210 days after date fully vaccinated was low, albeit higher in PWH versus PWoH overall (2.8% versus 2.1%, log-rank p<0.001, risk difference=0.7% [0.4%, 1.0%]) and within each vaccine type. Breakthrough infection risk was 41% higher in PWH versus PWoH (aHR=1.41 [1.28, 1.56]). Among PWH, younger age (18–24 versus 45–54), history of COVID-19 prior to fully vaccinated date, and J&J vaccination (versus Pfizer) were associated with increased risk of breakthroughs. There was no association of breakthrough with HIV viral load suppression or CD4 count among PWH. CONCLUSIONS AND RELEVANCE: COVID-19 vaccination is effective against infection with SARS-CoV-2 strains circulating through 30 Sept 2021. PWH have an increased risk of breakthrough infections compared to PWoH. Recommendations for additional vaccine doses should be expanded to all PWH. Cold Spring Harbor Laboratory 2021-12-05 /pmc/articles/PMC8669858/ /pubmed/34909791 http://dx.doi.org/10.1101/2021.12.02.21267182 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Coburn, Sally B.
Humes, Elizabeth
Lang, Raynell
Stewart, Cameron
Hogan, Brenna C
Gebo, Kelly A.
Napravnik, Sonia
Edwards, Jessie K.
Browne, Lindsay E.
Park, Lesley S.
Justice, Amy C.
Gordon, Kirsha
Horberg, Michael A.
Certa, Julia M.
Watson, Eric
Jefferson, Celeena R
Silverberg, Michael
Skarbinski, Jacek
Leyden, Wendy A
Williams, Carolyn F.
Althoff, Keri N.
COVID-19 infections post-vaccination by HIV status in the United States
title COVID-19 infections post-vaccination by HIV status in the United States
title_full COVID-19 infections post-vaccination by HIV status in the United States
title_fullStr COVID-19 infections post-vaccination by HIV status in the United States
title_full_unstemmed COVID-19 infections post-vaccination by HIV status in the United States
title_short COVID-19 infections post-vaccination by HIV status in the United States
title_sort covid-19 infections post-vaccination by hiv status in the united states
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669858/
https://www.ncbi.nlm.nih.gov/pubmed/34909791
http://dx.doi.org/10.1101/2021.12.02.21267182
work_keys_str_mv AT coburnsallyb covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT humeselizabeth covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT langraynell covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT stewartcameron covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT hoganbrennac covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT gebokellya covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT napravniksonia covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT edwardsjessiek covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT brownelindsaye covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT parklesleys covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT justiceamyc covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT gordonkirsha covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT horbergmichaela covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT certajuliam covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT watsoneric covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT jeffersonceleenar covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT silverbergmichael covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT skarbinskijacek covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT leydenwendya covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT williamscarolynf covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT althoffkerin covid19infectionspostvaccinationbyhivstatusintheunitedstates
AT covid19infectionspostvaccinationbyhivstatusintheunitedstates